ReviewCancer2015
Genetic variation as a modifier of association between therapeutic exposure and subsequent malignant neoplasms in cancer survivors.
Review in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Causes of death in patients with malignant adrenal tumours: a population-based analysis.Journal of endocrinological investigation · 2025Article
- Role of genetic modifiers on pulmonary consequences of cancer therapy in children.Scientific reports · 2025Article
- Melanoma Among Adult Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Risk of secondary myeloid neoplasms following treatment in patients with grade I-II follicular lymphoma: a retrospective cohort study.Discover oncology · 2025Article
- Clinicopathological features, prognostic factor analysis, and survival nomogram of patients with double primary cancers involving lung cancer.Cancer medicine · 2024Article
- Review
- Pan-cancer analysis of the prognostic and immunological role of nucleophosmin/nucleoplasmin 3 (Cancer pathogenesis and therapy · 2023Article
- Characteristics and survival analysis of breast cancer survivors with metachronous double primary cancers: a retrospective cohort study.Translational cancer research · 2023Article
- Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies.Hematology. American Society of Hematology. Education Program · 2022Article
- Impact of Methionine Synthase Reductase Polymorphisms in Chronic Myeloid Leukemia Patients.Genes · 2022Article
- Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.Journal of cancer research and clinical oncology · 2022Article
- Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center.International journal of clinical oncology · 2021Article
- Article
- The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress.Pediatric clinics of North America · 2020Review
- Musashi expression in intestinal stem cells attenuates radiation-induced decline in intestinal permeability and survival in Drosophila.Scientific reports · 2020Article
- In vitro analysis reveals necroptotic signaling does not provoke DNA damage or HPRT mutations.Cell death & disease · 2020Article
- Current and coming challenges in the management of the survivorship population.Seminars in oncology · 2020Review
- Therapeutic implications of germline genetic findings in cancer.Nature reviews. Clinical oncology · 2019Review
- Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era.JAMA oncology · 2019Article
- Polymorphisms in MDM2 and TP53 Genes and Risk of Developing Therapy-Related Myeloid Neoplasms.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Subsequent malignant neoplasms (SMNs) are associated with significant morbidity and are a major cause of premature mortality among cancer survivors. Several large studies have demonstrated a strong association between the radiation and/or chemotherapy used to treat primary cancer and the risk of developing SMNs. However, for any given therapeutic exposure, the risk of developing an SMN varies between individuals. Genomic variation can potentially modify the association between therapeutic exposures and SMN risk and may explain the observed interindividual variability. In this review, the author provides a brief overview of the current knowledge regarding the role of genomic variation in the development of therapy-related SMNs and discusses the methodological challenges in undertaking an endeavor to develop a deeper understanding of the molecular underpinnings of therapy-related SMNs, such as an appropriate study design, the identification of an adequately sized study population together with a reliable plan for collecting and maintaining high-quality DNA, clinical validation of the phenotype, and the selection of an appropriate approach or platform for genotyping. Understanding the factors that can modify the risk of treatment-related SMNs is critical to developing targeted intervention strategies and optimizing risk-based health care for cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.